Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Gynecol Oncol. 2019 Aug 30;155(2):324–330. doi: 10.1016/j.ygyno.2019.08.021

Figure 2. Validation of TCGA cluster survival results in the TCGA-155 and MCW-61 cohorts using 173 common antibodies.

Figure 2.

Tumors from the TCGA-155 (A) and MCW-61 (B) cohorts were assigned to survival-associated clusters that were previously identified by TCGA (EMT, Hormone, and PI3K/AKT). In agreement with the original TCGA data, we found that overall survival was significantly better for patients assigned to the hormone cluster and significantly worse for those within the EMT cluster in both TCGA-155 and MCW-61 cohorts in our analysis of expression data from the 173 common antibodies across RPPA platforms.